Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,779 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Follow-Up Questions
Who is the CEO of Takara Bio Inc?
Mr. Koichi Nakao is the President of Takara Bio Inc, joining the firm since 2007.
What is the price performance of TKBIF stock?
The current price of TKBIF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Takara Bio Inc?
Takara Bio Inc belongs to Biotechnology industry and the sector is Health Care
What is Takara Bio Inc market cap?
Takara Bio Inc's current market cap is $0
Is Takara Bio Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Takara Bio Inc, including 1 strong buy, 3 buy, 4 hold, 0 sell, and 1 strong sell
